Log on / register
BioMed Central home | Journals A-Z | Feedback | Support | My details
Open AccessHypothesis

Does CD4+CD25+foxp3+ cell (Treg) and IL-10 profile determine susceptibility to immune reconstitution inflammatory syndrome (IRIS) in HIV disease?

Esaki Muthu Shankar email, Ramachandran Vignesh email, Vijayakumar Velu email, Kailapuri G Murugavel email, Ramalingam Sekar email, Pachamuthu Balakrishnan email, Charmaine AC Lloyd email, Shanmugam Saravanan email, Suniti Solomon email and Nagalingeswaran Kumarasamy email

YRG Centre for AIDS Research and Education, VHS Hospital Campus, Rajiv Gandhi Salai-Information Technology Corridor, Taramani, Chennai 600 113, India

author email corresponding author email

Journal of Inflammation 2008, 5:2doi:10.1186/1476-9255-5-2

Published: 18 February 2008

Abstract

HIV-specific T-lymphocyte responses that underlie IRIS are incomplete and largely remain hypothetical. Of the several mechanisms presented by the host to control host immunological damage, Treg cells are believed to play a critical role. Using the available experimental evidence, it is proposed that enormous synthesis of conventional FoxP3- Th cells (responsive) often renders subjects inherently vulnerable to IRIS, whereas that of natural FoxP3+ Treg cell synthesis predominate among subjects that may not progress to IRIS. We also propose that IRIS non-developers generate precursor T-cells with a high avidity to generate CD4+CD25+FoxP3+ Tregs whereas IRIS developers generate T-cells of intermediate avidity yielding Th0 cells and effector T-cells to mediate the generation of proinflammatory cytokines in response to cell-signaling factors (IL-2, IL-6 etc.). Researchers have shown that IL-10 Tregs (along with TGF-β, a known anti-inflammatory cytokine) limit immune responses against microbial antigens in addition to effectively controlling HIV replication, the prime objective of HAART. Although certain technical limitations are described herein, we advocate measures to test the role of Tregs in IRIS.


© 1999-2009 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.